Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine

European Neuropsychopharmacology

Volumn 23, Issue 7, 2013, Pages 709-720

  Björkholm, Carl ^a   Jardemark, Kent ^a   Marcus, Monica M ^a   Malmerfelt, Anna ^a   Nyberg, Svante ^b   Schilström, Björn ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Antidepressant; Antipsychotic; Bipolar disorder; N desalkylquetiapine; Norquetiapine; Schizophrenia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DRUG METABOLITE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN TRANSPORTER; NORQUETIAPINE; QUETIAPINE; RACLOPRIDE TARTRATE; REBOXETINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ELECTROPHYSIOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; RECEPTOR OCCUPANCY; VENTROMEDIAL PREFRONTAL CORTEX;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZAZEPINES; DIBENZOTHIAZEPINES; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MEMBRANE POTENTIALS; MORPHOLINES; N-METHYLASPARTATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RACLOPRIDE; RATS;

EID: 84878891057     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.05.012     Document Type: Article

References (53)

1. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Van Heertum R., Gorman J.M., Laruelle M. Prefrontal dopamine d1 receptors and working memory in schizophrenia. J. Neurosci. 2002, 22:3708-3719.
2. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 1996, 16:19-30.
3. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 1997, 283:226-234.
4. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33:2175-2186.
5. Borison R.L., Arvanitis L.A., Miller B.G. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J. Clin. Psychopharmacol. 1996, 16:158-169.
6. Brugue E., Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(1):275-282.
7. Calabrese J.R., Keck P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 2005, 162:1351-1360.
8. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 1990, 55:1067-1070.
9. Chen L., Yang C.R. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J. Neurophysiol. 2002, 87:2324-2336.
10. Cutler A.J., Montgomery S.A., Feifel D., Lazarus A., Astrom M., Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J. Clin. Psychiatry 2009, 70:526-539.
11. Eltayb A., Wadenberg M.L., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Biol. Psychiatry 2005, 58:337-343.
12. Farde L., Nordström A.L. PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. Psychopharmacol. Ser. 1993, 10:94-100.
13. Farde L., Nordström A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 1992, 49:538-544.
14. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 2000, 22:642-649.
15. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D(1) receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berlin) 2004, 174:3-16.
16. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 1999, 286:105-107.
17. Hudzik T., Zhou J., Brockel B., Sutton E., Maciag C., Grimm S., Zeller Z., Widzowski D. Further characterization of norquetiapine and quetiapine in rodent models of antidepressant and anxiolytic action. Eur. Neuropsychopharmacol. 2008, 18:351-352.
18. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002, 956:349-357.
19. Jardemark K., Marcus M.M., Konradsson A., Svensson T.H. The combination of nicotine with the D2 antagonist raclopride or the weak D4 antagonist L-745,870 generates a clozapine-like facilitation of NMDA receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex. Int. J. Neuropsychopharmacol. 2005, 8:157-162.
20. Javitt D.C. Glutamatergic theories of schizophrenia. Isr. J. Psychiatry Relat. Sci. 2010, 47:4-16.
21. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
22. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
23. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., Meltzer H.Y. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006, 31:1991-2001.
24. Kirsch P., Ronshausen S., Mier D., Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry 2007, 40:196-198.
25. Li C.C. Change-Over Design. Introduction to Experimental Statistics 1964, McGraw-Hill Book Company, New York, pp. 207-226.
26. Linner L., Endersz H., Ohman D., Bengtsson F., Schalling M., Svensson T.H. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J. Pharmacol. Exp. Ther. 2001, 297:540-546.
27. Linner L., Wiker C., Wadenberg M.L., Schalling M., Svensson T.H. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D-2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2002, 27:691-698.
28. Marcus M.M., Jardemark K., Malmerfelt A., Bjorkholm C., Svensson T.H. Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. Neuropsychopharmacology 2010, 35:1952-1961.
29. Marcus M.M., Jardemark K., Malmerfelt A., Gertow J., Konradsson-Geuken A., Svensson T.H. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence. Synapse 2012, 66:277-290.
30. Marcus M.M., Jardemark K.E., Wadenberg M.L., Langlois X., Hertel P., Svensson T.H. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int. J. Neuropsychopharmacol. 2005, 8:315-327.
31. Marcus M.M., Nomikos G.G., Svensson T.H. Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur. Neuropsychopharmacol. 2000, 10:245-253.
32. Marcus M.M., Wiker C., Franberg O., Konradsson-Geuken A., Langlois X., Jardemark K., Svensson T.H. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int. J. Neuropsychopharmacol. 2010, 13:891-903.
33. Masana M., Bortolozzi A., Artigas F. Selective enhacement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14:53-68.
34. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 1990, 54:1755-1760.
35. Montgomery S.A. Reboxetine: additional benefits to the depressed patient. J. Psychopharmacol. 1997, 11:S9-S15.
36. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166:980-991.
37. Ninan I., Jardemark K.E., Wang R.Y. Differential effects of atypical and typical antipsychotic drugs on N-methyl-d-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 2003, 48:66-79.
38. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego, USA. fourth edition.
39. Popovic D., Reinares M., Goikolea J.M., Bonnin C.M., Gonzalez-Pinto A., Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur. Neuropsychopharmacol. 2012, 22(5):339-346.
40. Poyurovsky M., Faragian S., Fuchs C., Pashinian A. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study. Isr. J. Psychiatry Relat. Sci. 2009, 46:213-220.
41. Raedler T.J., Jahn H., Arlt J., Kiefer F., Schick M., Naber D., Wiedemann K. Adjunctive use of reboxetine in schizophrenia. Eur. Psychiatry 2004, 19:366-369.
42. Riedel M., Schennach-Wolff R., Musil R., Dehning S., Cerovecki A., Opgen-Rhein M., Matz J., Seemuller F., Obermeier M., Engel R.R., Muller N., Moller H.J., Spellmann I. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum. Psychopharmacol. 2010, 25:116-125.
43. Saeedi H., Remington G., Christensen B.K. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr. Res. 2006, 85:222-231.
44. Scornaiencki R., Cantrup R., Rushlow W.J., Rajakumar N. Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness. Int. J. Neuropsychopharmacol. 2009, 12:1195-1208.
45. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J. Psychopharmacol. 2007, 21:440-452.
46. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Rev. 2000, 31:320-329.
47. Wadenberg M.L., Wiker C., Svensson T.H. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. Int. J. Neuropsychopharmacol. 2007, 10:191-202.
48. Wadenberg M.-L.G., Soliman A., VanderSpek S.C., Kapur S. Dopamine d(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
49. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 2001, 412:127-138.
50. Yamamura S., Ohoyama K., Hamaguchi T., Kashimoto K., Nakagawa M., Kanehara S., Suzuki D., Matsumoto T., Motomura E., Shiroyama T., Okada M. Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology (Berlin) 2009, 206:243-258.
51. Yatham L.N., Goldstein J.M., Vieta E., Bowden C.L., Grunze H., Post R.M., Suppes T., Calabrese J.R. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry 2005, 66(Suppl. 5):40-48.
52. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., Bymaster F.P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000, 23:250-262.
53. Zheng P., Zhang X.X., Bunney B.S., Shi W.X. Opposite modulation of cortical N-methyl-d-aspartate receptor-mediated responses by low and high concentrations of dopamine. Neuroscience 1999, 91:527-535.